School of Public Health, Southeast University, Nanjing, PR China.
Department of Vaccine Clinical Evaluation, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, PR China.
Hum Vaccin Immunother. 2022 Dec 31;18(1):2027714. doi: 10.1080/21645515.2022.2027714. Epub 2022 Feb 22.
This study comprehensively evaluated and compared three human rabies vaccines. Seven electronic databases were systematically searched. The Cochrane Handbook v5.1.0 was used to assess the risk of bias. A random-effects model was used to combine individual rates, and network meta-analysis was used for pairwise comparisons. Twenty-seven articles were included, with a total of 18,630 participants. The pooled incidence of the total adverse reaction to HDCV was significantly lower than that of PCECV. HDCV administration resulted in a lower incidence of local pain, fever, and weakness than purified Vero cell vaccine. HDCV caused a lower incidence of local pain and fever than PCECV. No significant difference was observed in terms of the seroconversion rate on day 7 or the rabies virus-neutralizing antibody titer on day 14. HDCV demonstrated superiority in terms of safety compared with the other two rabies vaccines, while the same was not observed in terms of immunogenicity.
本研究综合评价和比较了三种人用狂犬病疫苗。系统检索了 7 个电子数据库。使用 Cochrane 手册 v5.1.0 评估偏倚风险。采用随机效应模型合并个体率,并进行网络荟萃分析进行两两比较。共纳入 27 篇文章,共计 18630 名参与者。HDCV 的总不良反应发生率明显低于 PCECV。HDCV 接种后局部疼痛、发热和乏力的发生率低于纯化 Vero 细胞疫苗。HDCV 引起的局部疼痛和发热发生率低于 PCECV。第 7 天的血清转化率或第 14 天的狂犬病病毒中和抗体滴度无显著差异。与其他两种狂犬病疫苗相比,HDCV 在安全性方面具有优势,但在免疫原性方面则没有。